Phospholipase C-g1(PLC-g1) is known to play an essential role in various cellular responses, such as proliferation and tumorigenesis, and PLC-g1-speci®c inhibitors are commonly employed to investigate the mechanism of the PLC-g1-mediated signaling pathway. In this study, we developed a single chain antibody fragment (scFv) as a blocker for PLC-g1 mediated signaling. scFv, designated F7-scFv, speci®cally bound to PLC-g1 with high anity (K d =1.9610 78 M) in vitro. F7-scFv also bound to PLC-g1 in vivo and altered the distribution pattern of PLC-g1 from the cytoplasm to the intracellular aggregates, where F7-scFv was localized. Moreover, F7-scFv interrupted the EGF-induced translocation of PLC-g1 from the cytosol to the membrane rue and attenuated EGF-induced inositol phosphates generation and intracellular calcium mobilization. These results indicate that F7-scFv blocks EGF-induced PLCg1 activation by causing sequestering of PLC-g1 into intracellular aggregates, and may therefore be useful in studies of the PLC-g1-mediated signaling pathway. Oncogene (2001) 20, 7954 ± 7964.
Introduction
Various extracellular signals, such as growth factors, hormones, and neurotransmitters exert their physiologic eects by activating Phospholipase C (PLC). Activated PLC hydrolyzes phosphoinositol 4,5-bisphosphate (PIP 2 ) to produce inositol 1,4,5-trisphosphate (IP 3 ) and diacylglycerol (DAG) . IP 3 and DAG serve as intracellular second messengers by mobilizing intracellular Ca 2+ and activating protein kinase C (PKC), respectively (Rhee and Choi, 1992; Cockcroft and Thomas, 1992; Berridge, 1993) . Currently, more than 11 mammalian PLC proteins have been identi®ed. Structural studies and sequence comparisons have led to the classi®cation of these PLCs into four types: b, g, d, and e (Rhee and Bae, 1997; Song et al., 2001) . Although the overall sequence homology of the four isotypes is quite low, they have two signi®cantly conserved regions (designated X and Y) that comprise the catalytic core.
In comparison with the other PLC isozymes, PLC-g has a unique array of domains, namely, an additional split pleckstrin homology (PH) domain, two src homology 2 (SH2) domains, and an SH3 domain (Katan, 1998) . The SH2 and SH3 domains mediate protein ± protein interactions by binding to phosphorylated tyrosine or proline rich sequences, respectively (Koch et al., 1991) . Activation of PLC-g is brought about either by receptor tyrosine kinases or nonreceptor tyrosine kinases, which phosphorylate PLC-g. Several lipid-derived second messengers, for example arachidonic acid and phosphatidylinositol 3,4,5-trisphosphate (PIP 3 ), can also activate PLC-g and induce PIP 2 hydrolysis (Rhee and Bae, 1997) . In addition to the lipase activity of PLC-g, protein ± protein interactions through the SH domain are also involved in the PLC-g-mediated signaling pathway. When a truncated PLC-g1 containing the SH2-SH2-SH3 domains (Smith et al., 1996) , or a lipase inactive mutant of PLC-g1 are microinjected into NIH3T3 cells, they induce DNA synthesis (Huang et al., 1995) , which indicates that the SH domain of PLC-g1 is involved in PLC-g1-mediated signaling. It was also reported that the SH3 domain of PLC-g1 interact with SOS-1, and is involved in SOS1-mediated p21 Ras activation (Kim et al., 2000) .
Numerous reports have shown that PLC-g1 is involved in cell proliferation and tumorigenesis. For example, growth factors and mitogens activate PLC-g1 (Kim et al., , 1991 . The overexpression of PLC-g1 induces DNA synthesis in NIH3T3 (Smith et al., 1990) and 3Y1 rat ®broblasts that overexpress PLC-g1 induce tumors in nude mice (Chang et al., 1997) . Certain tumors, such as familial adenomatous polyposis , colorectal cancer Lee et al., 1995) , and breast cancer (Arteaga et al., 1991) show elevated PLC-g1 expression. These results suggest that PLC-g1 can be a target for tumor therapy. To understand the PLC-g1 mediated proliferation and tumorigenesis mechanisms, several investigatory tech-niques have been used, including the overexpression of PLC-g1, generation of PLC-g1 knock-out mice (Ji et al., 1997) , or the microinjection of anti-PLC-g1 antibody. However, the mechanism of PLC-g1-mediated proliferation and tumorigenesis is not understood. Therefore, a PLC-g1-speci®c inhibitor is required to study the mechanism of PLC-g1-mediated signaling in further detail and to apply in tumor therapy.
Microinjection of antibodies into cells has been employed to interrupt the function of speci®c proteins (Smith et al., 1994) , but this method has several limitations, as microinjected antibodies undergo proteolysis within the cells, and only short-term and fast biological responses can be studied. Recently, the intracellular expression of a single chain antibody fragment (scFv) has been used as an alternative antibody microinjection (Biocca and Cattaneo, 1995) . The scFv used was a polypeptide, which consisted of an antibody heavy chain and a light chain variable region connected by a¯exible linker. Various scFvs have been developed and expressed in cells with the intention of interrupting the functions of several molecules to which scFv binds (Richardson and Marasco, 1995) . For instance, the intracellular expression of scFv, which originated from the neutralizing antibody of ras regressed tumor (Cochet et al., 1998) , and anti-ErbB2 scFv, which was modi®ed to contain the ER retention signal peptide, inhibited tumor cell growth by changing the site of localization of erbB2 from the plasma membrane to ER (Beerli et al., 1994) .
It has been previously reported that the monoclonal anti-PLC-g1 antibody, F7, inhibits PLC-g1 activity (Suh et al., 1988) , and that microinjected F7 decreases serum-, ras-, and PLC-g1-induced DNA synthesis (Smith et al., 1990 (Smith et al., , 1994 . In the present investigation, we developed an scFv from F7 to create an agent designed to block the activation of PLC-g1. The scFv, named F7-scFv, bound to PLC-g1 with high anity (1.9610 78 M) and colocalized with PLC-g1 in cell. Moreover, the intracellular expression of F7-scFv disturbed the EGF-induced translocation of PLC-g1, inositol phosphates generation and intracellular calcium mobilization. F7-scFv may be useful in the investigation of PLC-g1-mediated signaling mechanisms and tumor therapy by delivering the F7-scFv gene into cells and speci®cally interrupting the activation of PLC-g1.
Results

Development of scFv from hybridoma cells producing F7
To develop a blocker for PLC-g1, we constructed scFv using RNA puri®ed from hybridoma cells producing F7. Hybridoma cells have mRNAs that can encode functional antibody and several nonfunctional antibodies. The nonfunctional antibodies have premature in-frame stop codons. Therefore, the expression of scFv distinguishes full-length scFv from scFvs that originated from nonfunctional antibodies.
For this purpose, we designed a pTFvASN prokaryotic expression vector to express scFv-angiogenin fusion protein. Angiogenin was fused to the carboxyl-terminal of scFv to emphasize the size dierence between the full-length and fragmented scFvs. S®I and NotI restriction enzyme sites were also introduced into the 5'-end of the angiogenin gene in pTFvASN (Figure 1a) .
scFv genes constructed from hybridoma secreting F7 were subcloned into pTFvASN and expressed in E. coli BL21. Seven out of 13 clones expressed the 44.5 kDa scFv-angiogenin fusion protein (Figure 1b) . The other scFv proteins that had molecular weights of less than 44.5 kDa were expected to have originated from mRNA transcribed from non-functional antibody genes.
We determined the nucleotide and derived amino acid sequences of the scFv genes that expressed the 44.5 kDa fusion protein ( Figure 2 ). All four clones examined had identical nucleotide sequences. According to Kabat's classi®cation (Kabat et al., 1991) , VH of the scFv (designated F7-scFv) belongs to the mouse heavy chain subfamily VII, and VL is a novel member of the mouse k light chain miscellaneous subfamily. scFv genes constructed from hybridoma secreting F7 were subcloned into pTFvASN and transformed to BL21 E.coli strain. Expression of scFv-angiogenin was induced in individual colonies by adding IPTG. Cell lysates were subjected to SDS ± PAGE and stained with Coomassie blue. 1, 2, 5, 7, 8, 10, and 13 clones expressed scFv-angiogenin fusion protein with molecular weight 44.5 kDa F7-scFv binds to PLC-g1 with high affinity
We characterized the binding capacity of F7-scFv to PLC-g1 by ELISA and by immunoprecipitation analysis. When F7-scFv was expressed in E. coli BL21 using pRSET S®I/NotI prokaryotic expression vector (Yi et al., 1999) inclusion bodies which was purely composed of F7-scFv were formed. To obtain soluble F7-scFv, the inclusion bodies were denatured using guanidine HCl and renatured by dialysis. The soluble F7-scFv bound to puri®ed PLC-g1, while CEA79-scFv, which recognizes carcinoembryonic antigen (Yi et al., 1999) , did not (Figure 3a) . After mixing the soluble F7-scFv with COS-7 cell lysate, PLC-g1 was precipitated with anti-PLC-g1 antibody, which recognizes the 10 amino acids at the C-terminus of PLC-g1 (RTRVNGDNRL). F7-scFv was coprecipitated with PLC-g1, whereas CEA79-scFv was not (Figure 3b ). This result suggests that F7-scFv recognizes PLC-g1. We also identi®ed with several PLC-g1 mutants that the F7-scFv recognized SH3 domain of PLC-g1 to which F7 binds.
The binding anity of F7-scFv was also measured by competition ELISA and surface plasmon resonance Figure 2 Nucleotide sequence of F7-scFv and the deduced amino acid sequence. The complementarity-determining regions (CDR) H1, H2, H3, L1, L2, L3, and the¯exible (Gly 4 Ser) 3 linker are underlined. VH of F7-scFv belongs to the mouse heavy chain subfamily VII, and VL is a novel member of the mouse k light chain miscellaneous subfamily. The sequence has been deposited in the GenBank database (accession number AF367377) in a BIAcore instrument (Biacore AB, Uppsala, Sweden). F7-scFv was incubated with various concentrations of puri®ed PLC-g1 until equilibrium was reached, and the amount of free F7-scFv at equilibrium was measured by ELISA (McCaerty et al., 1996) . The equilibrium dissociation constants (K d ) of F7-scFv and F7 were determined by Scatchard analysis to be 1.9610
78 M and 0.8610 79 M, respectively ( Figure 4 ).
These values were consistent with the value of K d calculated from sensorgrams for the binding of F7-
79 M) to PLC-g1 immobilized on a CM-5 chip. Though F7-scFv has a high anity for PLC-g1, it showed a 20-fold lower binding anity than F7. F7-scFv is a fragment of F7 and has a linker peptide between VH and VL. This structural dierence between F7-scFv and F7 might in¯uence the binding anity of F7-scFv for PLC-g1.
Colocalization of F7-scFv with PLC-g1
To investigate the binding characteristics of F7-scFv to PLC-g1 in cells, F7-scFv was tagged with Xpress, subcloned into pcDNA eukaryotic expression vector and expressed in COS-7 cells. When expressed in COS- Figure 3 F7-scFv binds to PLC-g1. (a) Puri®ed PLC-g1 was coated on a ELISA plate and Xpress tagged-F7-scFv was applied. After washing, bound F7-scFv was detected with anti-Xpress antibody, and then horseradish peroxidase conjugated anti-mouse Ig GAM. The product of horseradish peroxidase was measured by ELISA reader at absorbance 405 nm. F7-scFv speci®cally bound to PLC-g1 but Xpress tagged-CEA79-scFv, which recognizes carcinoembryonic antigen did not. (b) Puri®ed Xpress tagged-F7-scFv or CEA79-scFv were added to COS-7 cell lysate, and PLC-g1 was immunoprecipitated from the mixture with anti-PLC-g1 antibody, which recognizes the 10 amino acids at the Cterminus of PLC-g1. Precipitated PLC-g1 and scFv were detected by immunoblot. F7-scFv coprecipitated with PLC-g1, whereas CEA79-scFv did not 7 cells, F7-scFv was detected in a 1% Triton X-100 insoluble fraction ( Figure 5a ). We also observed that F7-scFv formed intracellular aggregates (Figure 5b ), a property of highly insoluble proteins, by immuno¯uor-escence staining.
To con®rm that insoluble F7-scFv can bind to PLCg1 in cells, F7-scFv was co-transfected with PLC-g1 to COS-7 cells and its intracellular distribution was visualized by immuno¯uorescence staining. F7-scFv was detected by TRITC-coupled anti-Xpress antibody and PLC-g1 was detected by FITC-coupled anti-PLCg1 antibody (B16) (Suh et al., 1988) . PLC-g1 was detected in the cytosol in a single transfected cell. However, the co-expression of F7-scFv and PLC-g1 altered the distribution pattern of PLC-g1 to the punctate form, as occurred for F7-scFv. The localization of F7-scFv and PLC-g1 were merged when the two images were superimposed ( Figure 6 ). These results indicate that intracellularly expressed F7-scFv retains the ability to bind to PLC-g1, although F7-scFv forms intracellular aggregations.
F7-scFv interrupts EGF-induced activation of PLC-g1
It is known that PLC-g1 translocates from the cytosol to membrane rue upon EGF treatment (Diakonova et al., 1995) . Hence, we investigated the eect of F7-scFv on the EGF-induced translocation of PLC-g1. After EGF treatment, the PLC-g1 previously located in the cytosol of serum-depleted COS-7 cells translocated to the membrane rues (Figure 7a) . However, the EGF-induced translocation of PLC-g1 was interrupted by the expression of F7-scFv, as it remained with F7-scFv in the intracellular aggregates after EGF treatment (Figure 7b ).
To further investigate the eect of F7-scFv on the PLC-g1-mediated signaling pathway, EGF-induced inositol phosphates generation and intracellular calcium mobilization were analysed. After transfection with dierent concentrations of pcDNA-F7-scFv, we stimulated cells with EGF and measured the inositol phosphates so generated. As the expression level of F7-scFv increased, EGF-induced inositol phosphates generation reduced (Figure 8 ). F7-scFv was subcloned into the pEGFP-N1 vector to enable the detection of expression as a fusion protein with enhanced green¯uorescent protein (EGFP). The F7-scFv/EGFP formed intracellular aggregates and distributed as punctate pattern as F7-scFv in cells, which is showing that the EGFP fusion did change the character of F7-scFv. After transfection of F7-scFv/EGFP, EGF-induced cytosolic calcium transition was monitored by collecting sequential¯uores-cent images of individual COS-7 cells loaded with the Ca 2+ -sensitive¯uorescent dye, fura-2. As compared with untransfected cells or vector-transfected cells, cells expressing F7-scFv/EGFP did not mobilize intracellular calcium after EGF treatment ( Figure  9 ). The expression of F7-scFv or F7-scFv/EGFP did not change the EGF-induced tyrosine phosphorylation of EGF receptor. These results suggest that the intracellular expression of F7-scFv speci®cally inactivates PLC-g1 in cell.
Discussion
In this study, we have demonstrated that F7-scFv, derived from the monoclonal anti-PLC-g1 antibody F7, is a potent eector molecule that can block the EGF-induced activation of PLC-g1. It has been well established that PLC-g1 is a substrate of the EGFreceptor tyrosine kinase (Meisenhelder et al., 1989; Margolis et al., 1989) , and that the binding of EGF to its receptor results in the phosphorylation and activation of the EGF receptor, which in turn phosphorylates and activates PLC-g1. The SH2 domain of PLC-g1 binds to phosphotyrosine-containing residues in the activated EGF-receptor, and mediates the interaction between activated EGF Figure 5 Expression of F7-scFv in COS7 cells. (a) COS-7 cells expressing Xpress tagged-F7-scFv were lyzed with PBS containing 1% Triton X-100, then centrifuged at 16 000 g for 5 min. The scFv band was detected by anti-Xpress antibody only in the Triton X-100 insoluble fraction. (b) Xpress tagged-F7-scFv was expressed in COS-7 cells, and then visualized by immuno¯uores-cence staining using TRITC-coupled anti-Xpress antibody. F7-scFv was distributed in a punctate manner receptor and PLC-g1 (Anderson et al., 1990) . It has also been reported that EGF causes a redistribution of PLC-g1 from the cytoplasm to the plasma membrane (Diakonova et al., 1995) . In accordance with previous reports, we observed EGF-induced translocation and activation of PLC-g1 in COS-7 cells. The expression of F7-scFv in COS-7 cells abolished the translocation and activation of PLC-g1, which eectively demonstrated that F7-scFv could interrupt the PLC-g1-mediated signaling pathway. However, we could not Figure 6 PLC-g1 colocalized with F7-scFv in COS-7 cells. Xpress tagged-F7-scFv and PLC-g1 were co-expressed in COS-7 cells, then stained with TRITC-coupled anti-Xpress antibody and FITC-coupled anti-PLC-g1 antibody. When expressed in COS-7 cells, F7-scFv formed punctate pattern (2) and PLC-g1 dispersed in the cytosol (1, arrowhead). Co-expression of PLC-g1 with F7-scFv altered the distribution pattern of PLC-g1 to the punctate form (1, arrow). Localization patterns of F7-scFv and PLC-g1 were superimposed (3). The pictures are the representatives of more than 20 cells Figure 7 Inhibitory eect of F7-scFv on the EGF-induced translocation of PLC-g1. (a) COS-7 cells transfected with PLC-g1 were stimulated with 100 ng/ml of EGF for 5 min after serum depletion for 24 h. Localization of PLC-g1 was visualized by staining with FITC-coupled anti-PLC-g1 antibody in serum depleted (left) and in EGF treatmented COS-7 cell (right). PLC-g1 was translocated to the plasma membrane (arrows) by the EGF treatment. (b) COS-7 cells, which express PLC-g1 and Xpress tagged-F7-scFv were treated with 100 ng/ml of EGF for 5 min. PLC-g1 and F7-scFv were stained with FITC-coupled anti-PLC-g1 antibody and TRITCcoupled anti-Xpress antibody. The PLC-g1 was localized in intracellular aggregates (1) where F7-scFv was (2) and did not translocate to membrane rues. The merged image is shown (3). These images are representatives of similar results obtained from more than 15 cells in three separate experiments Oncogene Interruption of PLC-g1-mediated signaling by scFv KS Yi et al observe complete inhibition of EGF-induced inositol phosphates generation by F7-scFv expression. F7-scFv was transiently expressed in COS-7 cells with 30 ± 40% transfection eciency determined by immunocytochemistry. When we consider the complete inhibition of Ca 2+ mobilization in F7-scFv/EGFP-transfected cells, about 30% inhibition of EGF-induced inositol phosphates generation by transfection of F7-scFv is comparable to the transfection eciency.
Several reports suggest that PLC-g1 is involved in the cell proliferation signal and is related to antiapoptosis. Suppressed expression of PLC-g1 by antisense RNA reduced cell proliferation (Nebigil, 1997) , and homozygous disruption of Plcg1(PLC-g1 gene) lead to embryo death at embryonic day 9 (Ji et al., 1997) . Previously, we reported that PLC-g1 is fragmented in Molt 4 cells by several apoptotic stimuli, and those PLC inhibitors, such as U-73122 or ET-18-OCH3, induced apoptosis (Bae et al., 2000) . These reports indicate that defects in the PLC-g1-mediated signaling pathway can facilitate apoptosis. In this study, we observed that cells died during selection to establish cell lines that constitutively express F7-scFv. This result suggests that F7-scFv may inhibit cell proliferation and induce cell death by disrupting PLCg1-mediated cell proliferation. B cells, which are the fusion components of hybridoma, may have several mRNAs transcribed from dierent antibody genes. B cells undergo rearrangements of the immunoglobulin gene in an ordered sequence during maturation, until a functional antibody gene is generated. Improper antibody genes are produced during a rearrangement that contains premature in-frame termination codons, and the elimination of the improper heavy or light chain is regulated at a post-transcriptional and post-translational level. As a result, B cells may contain several dierent mRNAs encoding antibodies (Lozano et al., 1993 (Lozano et al., , 1994 . In summary, we expressed scFvs that were constructed from hybridoma secreting F7 in order to eliminate improper scFv containing stop codons, and angiogenin gene was fused in frame to the carboxylterminal of scFv to enable the identi®cation of scFvs that contain a stop codon near the end of the scFv. Several antigen-speci®c scFvs have been generated by screening libraries constructed from non-immunized and immunized animals, or hybridoma cells (Hoogenboom et al., 1998). Phage display technology was used to screen an scFv that has high anity to the target antigen. This technology includes a repeated panning and amplifying process from an antibody-displaying phage library. Screening of scFv using its expression as a fusion protein is less laborious and time-consuming than using phage display technology. We suggest that screening of scFv based upon its expression, which is the method used in this report, should be employed as an alternative screening method when scFv is constructed from hybridoma.
In agreement with earlier reports (Cattaneo and Biocca, 1999; Nieba et al., 1997), F7-scFv formed intracellular aggregates, which is a typical pattern of insoluble proteins. Due to the reducing environment of the cell cytoplasm, intracellularly expressed scFvs cannot form proper disul®de bonds, which are important for antibody structure, and this disruption of disul®de bonds may change the structure of scFv and in¯uence its solubility (Cattaneo and Biocca, 1999) . Truncation of the structure of scFv can also change its solubility. Hydrophobic patches at the antibody variable/constant domain interface are exposed to the aqueous environment by scFv construction and increase the hydrophobicity of scFv (Nieba et al., 1997) . These factors may induce scFvs aggregation in cells. However, in some cases, the folding intermediates may have a native-like structure. For example, anti-p21 ras scFv forms aggregates in the cytosol, but binds antigen, and sequesters it within the aggregates (Cardinale et al., 1998) . F7-scFv also generated aggregates in the cell, but it could bind and trap PLC-g1 as anti-p21 ras scFv. In the steadystate, intracellular scFvs are evidently insoluble. However, during the intermediate folding state before aggregate formation, it is hypothesized that they retain a native structure, and can therefore bind antigen (Wetzel, 1994) . Following this initial binding event, intermediate scFvs form aggregates, which entrap bound antigen. In conclusion, we constructed F7-scFv from hybridoma, which secret monoclonal anti-PLC-g1, F7. This F7-scFv bound PLC-g1 with high anity and blocked the EGF-induced activation of PLC-g1. The F7-scFv may be useful in the study of PLC-g1-mediated signaling mechanisms and tumor therapy by selective disruption of PLC-g1 activation.
Materials and methods
Construction of pTFvASN and scFv
pTFvASN vector was constructed by PCR from pRSET prokaryotic expression vector (Invitrogen) into which the human angiogenin gene had been subcloned. The pRSETangiogenin vector was ampli®ed with forward primer (5'-CCC GGC CGG CTG GGC CGC CTT ATC GTC ATC GTC GTA CAG ATC-3'), and reverse primer (5'-CGG GCG GCC GCA GGC GGT GGC GGA TCG GGC GGA GGT GGC TCT GGT GGA GGC GGC AGC CAG GAT AAC TCC AGG TAC ACA-3'). PCR conditions were 5 min at 958C, followed by 30 cycles of 1 min at 958C, 1 min at 558C, and 10 min at 728C.
Total RNA was isolated from hybridoma cells secreting F7 (Suh et al., 1988 ). An ultraspec RNA isolation system (Biotecx) was used according to the manufacturer's instructions. ScFv gene was prepared using the mouse scFv module/recombinant phage display system (Amersham Pharmacia) according to manufacturer's instructions, but with some modi®cation. In brief, puri®ed RNA was used for random primed cDNA synthesis. The resulting singlestranded DNA was used for the primary ampli®cation of VH and VL using a mixture of VH-or VL-speci®c primers. Following ampli®cation, VH and VL were assembled using a linker sequence that encodes (Gly 4 Ser) 3 and ampli®ed again with a mixture of VH-speci®c primers containing an S®I site at the 5' end and a mixture of VL-speci®c primers with a NotI site at the 3' end. The PCR products were then digested with S®I and NotI, and ligated with pTFvASN digested with S®I and NotI.
Expression of scFv-angiogenin fusion protein
The BL21 E. coli strain (Novagen) was transformed using the pTFvASN-scFv ligation mixture and spread on an LB plate containing ampicillin. After culturing, each colony in LB media containing 50 mg/ml of ampicillin at 378C, 0.5 mM IPTG was added and incubated for 3 h to induce the expression of scFv-angiogenin fusion protein. E. coli cells were harvested by centrifugation at 16 000 g for 2 min, and then resuspended with SDS gel-loading buer (50 mM Tris pH 6.8, 100 mM dithiothreitol (DTT), 2% sodium dodecyl The pseudocolor image of F7-scFv/EGFP positive (arrow) and negative cell (arrowhead) was acquired before and after EGF treatment. The pseudocolor of F7-scFv/EGFP negative cell changed from black to purple, but the pseudocolor of F7-scFv/EGFP positive cells remained black even after EGF treatment sulfate (SDS), 0.1% bromophenol blue, 10% glycerol). SDS ± PAGE was performed using a 12% polyacrylamide gel, and stained with Coomassie brilliant blue.
Sequence analysis
The selected F7-scFv gene was excised from pTFvASN-scFv and subcloned into the S®I and the NotI sites of pCANTAB5E (Amersham Pharmacia). The DNA sequence of F7-scFv was determined using the dideoxy chain termination method using S1, S3, S4, and S6 primers (Amersham Pharmacia).
Preparation of F7-scFv protein E. coli BL21 cells harboring pRSET S®I/NotI vector (Yi et al., 1999) containing F7-scFv, were grown in 26YT media with 50 mg/ml of ampicillin at 378C. Expression of F7-scFv was induced by adding 0.5 mM of IPTG at an OD 600 =0.5, and this was followed by incubation at 378C for 5 h. Cells were harvested by centrifugation at 6000 g for 10 min, suspended in PBS and sonicated. After centrifugation at 24 300 g for 1 h at 48C, the resulting pellet was solubilized in denaturation buer (50 mM Tris pH 7.6, 6 M Guanidine hydrochloride (GuHCl), 1 mM EDTA, 10 mM 2-mercaptoethanol (2-ME)) and incubated at room temperature for 1 h. Insoluble debris was removed by centrifugation at 24 300 g for 1 h. After removing 2-ME by dialysis against 6 M GuHCl refolding buer (50 mM Tris pH 7.6, 6 M GuHCl, 1 mM EDTA, 200 mM NaCl), GuHCl was removed by serial dialysis against GuHCl refolding buer (50 mM Tris pH 7.6, 1 mM EDTA, 200 mM NaCl, GuHCl). The GuHCl concentration was reduced step-wisely (3, 2, 1, 0.5 and 0.1 M). When dialyzed against 1 M GuHCl refolding buer, 375 mM oxidized glutathione (GSSG) and 400 mM L-arginine were added (Tsumoto et al., 1998) .
ELISA PLC-g1 was puri®ed from Sf9 cells as described previously (Bae et al., 2000) . Microtiter plates were coated with 10 mg/ ml puri®ed PLC-g1 in sodium carbonate buer (pH 8.6). The plates were washed twice with distilled water and blocked with 5% BSA in PBS (5% bovine serum albumin in PBS). F7, Xpress tagged-F7-scFv or Xpress tagged-CEA79-scFv were added to the plates and incubated for 6 h at room temperature. After washing with TPBS (PBS with 0.05% Tween 20, pH 7.2), monoclonal anti-Xpress antibody was applied on the plates where scFvs were added, and incubated 1 h at room temperature. After washing, bound anti-Xpress antibody or F7 was detected with horseradish peroxidase conjugated anti-mouse Ig GAM and 1-step ABTS peroxidase substrate solution (Pierce).
Immunoprecipitation
Polyclonal anti-PLC-g1 antibody that recognizes the Cterminal of PLC-g1 (RTRVNGDNRL) was immobilized on protein A agarose. COS7 cell lysates (800 mg) and 2 mg of CEA79-scFv (Yi et al., 1999) or F7-scFv were then incubated with immobilized antibody for 4 h at 48C. The immune complexes were washed ®ve times with PBS containing 1% Triton X-100, and ®nally suspended in 50 ml of SDS gel-loading buer (50 mM Tris pH 6.8, 100 mM DTT, 2% SDS, 0.1% bromophenol blue, 10% glycerol). The complexes were then subjected to SDS ± PAGE and Western blot analysis.
Western blot
Proteins separated by SDS ± PAGE were electrotransferred onto nitrocellulose paper and incubated with 5% skimmed milk in TTBS (10 mM Tris pH 7.6, 150 mM NaCl, 0.05% Tween 20). The blot was then incubated for 2 h at room temperature with either monoclonal anti-Xpress antibody to detect coprecipitated Xpress tagged-scFvs, or with F7 to detect PLC-g1. The blot was subsequently washed with TTBS and incubated with horseradish peroxidase-conjugated antimouse Ig GAM for 1 h at room temperature. After washing with TTBS, the immunoblot was developed by enhanced chemiluminescence (ECL, Amersham Pharmacia).
Affinity measurement
The dissociation constants (K d ) of F7-scFv and F7 were determined by competitive ELISA. Wells of a microtiter plate were coated with 50 ml of sodium carbonate buer (15 mM Na 2 CO 3 , 35 mM NaHCO 3 , pH 9.6) containing 10 mg/ml of PLC-g1 puri®ed from Sf9 cells, as described previously (Bae et al., 2000) . The plates were washed twice with distilled water and blocked with 5% bovine serum albumin (BSA) in PBS. F7-scFv or F7 was incubated with various concentrations of PLC-g1 (1610 76 M, 2.5610 77 M, 1.6610
3.9610 79 M) for 12 h to allow equilibration, and then the mixture was added to the PLC-g1-coated microtiter plates. After 1 h incubation at room temperature and washing with TPBS (PBS with 0.05% Tween 20, pH 7.2), bound F7-scFv or F7 were detected with monoclonal anti-Xpress antibody (Invitrogen), horseradish peroxidase conjugated anti-mouse Ig GAM (Kirkegaard & Perry Laboratories) and 1-step ABTS peroxidase substrate solution (Pierce). A Scatchard plot was drawn with V/Ag on the y-axis and V on the x-axis, where Ag is the concentration of soluble PLC-g1 and V is the fraction of antibody bound to PLC-g1 in the soluble phase. The value of V was obtained by dividing the absorbance decrease that occurred after the addition of PLC-g1 to the soluble phase by the absorbance in the absence of soluble PLC-g1. The slope of the straight line generated is equal to 71/K d (McCaerty et al., 1996) . PLC-g1 was immobilized to the dextran surface of a CM5 sensor chip (Amersham Pharmacia) by amine coupling with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) and N-hydrosuccinimide (NHS) to a density of 4500 ± 6000 response units (RU). Several concentrations of F7-scFv or monoclonal F7 antibody diluted in HBS (10 mM HEPES pH 7.4, 150 mM NaCl, 3.4 mM EDTA, 0.005% surfactant P20) were applied using the kinject program at 30 ml/min for 5 min with a 5 min dissociation time. The bound F7-scFv or monoclonal F7 antibody was stripped from the PLC-g1 coupled dextran surface using 10 mM glicine, pH 2. The K d value was obtained by subjecting the sensorgrams to global analysis using BIAevaluation software 3.0.
Immunocytochemistry COS-7 cells were cultured with DMEM supplemented with 10% fetal calf serum. For immunocytochemistry, COS-7 cells were grown on glass coverslips coated with 10 mg/ml of poly L-lysine. pCMV-PLC-g1 and pcDNA-F7-scFv were cotransfected using fugene 6 (Roche). The transfected cells were grown in the presence of serum for 24 h, and then cultured for an additional 24 h either with or without serum. Serum starved cells were stimulated with 100 ng/ml EGF for 5 min. After washing with PBS, 4% paraformaldehyde was added and incubated for 10 min for ®xation. The cells were washed with PBS and permeabilized by incubating with 0.2% Triton X-100 in PBS for 10 min. After blocking with 2% BSA, the cells were incubated with TRITC coupled antiXpress antibody and FITC coupled anti-PLC-g1 antibody, B16, (Suh et al., 1988) for 1 h. After washing with PBS, the coverslips were mounted on slides, and the cells were photographed using an inverted¯uorescence microscope (Axiovert 135, Zeiss).
Measurement of inositol phosphates
1.5610 5 COS-7 cells cultured in DMEM supplemented with 10% fetal calf serum were transfected with dierent concentration of pcDNA-F7-scFv or pcDNA using fugene 6 (Roche). After 24 h, cells were labeled with myo-[2-3 H]inositol (1 mCi/ml) in inositol-free DMEM for 24 h. The cells were then washed and pre-treated with 20 mM LiCl for 20 min in inositol-free DMEM. EGF (100 ng/ml) was treated for 15 min and stimulation was terminated by adding 0.4 ml of ice-cold 5% HClO 4 . After 30 min on ice, the extracts were centrifuged, diluted 1 : 2 with distilled water and applied to a Dowex AG 1-X8 anion exchange column (BioRad). Total inositol phosphate was eluted from the column, with a solution containing 1 M ammonium formate and 0.1 M formic acid, and quanti®ed by liquid scintillation counting.
Digital fluorescence ratio imaging of cytosolic Ca 2+ F7-scFv was subcloned to pEGFP-N1 and transfected using fugene 6 into COS-7 cells grown on glass coverslips coated with 10 mg/ml poly L-lysine. After 24 h, the serum was depleted for 18 h. Cells were then incubated with 6 mM Fura-2/AM and 250 mM sul®npyrazone for 2 h, and the coverslips mounted on a te¯on recording chamber under a Nikon inverted-stage microscope. This was followed by continuous perfusion with Locke's solution (154 mM NaCl, 5.6 mM KCl, 2.2 mM CaCl 2 , 1.2 mM MgCl 2 , 10 mM glucose, and 5 mM HEPES buer adjusted to pH 7.4). Sul®npyrazone (250 mM) was added to all solutions to prevent dye leakage. The perfusion system was combined with an eight-port valve control system (ALA Scienti®c Instruments Inc., Westbury, NY, USA) to allow switching between the solutions that contained the dierent agents being tested. EGFP or F7-scFv/EGFP expressed cells were detected by excitation at 480 nm. Cells were stimulated with 200 ng/ml of EGF and changes in fura-2¯uorescence were monitored. Light from a 250-W Xenon lamp was ®ltered through two dierent bandpass ®lters (340 and 380 nm) in the excitation path and the specimen was illuminated on the microscope stage using a dichromic mirror. Excitation wavelengths of 340 and 380 nm were alternately applied to the cells, and¯uorescence at 4510 nm was monitored with an intensi®ed CCD camera (Hamamatsu Photonics, Hamamatsu, Japan). Output from the camera was digitized and stored by a computerized imaging system (Universal Imaging, West Chester, PA, USA). 5126480 pixel images were captured at 256 intensity values. The software (Meta¯uor version 4.01, Universal Imaging Corp.) performed the background subtraction, shading correction, and then calculated the 340 ± 380 nm ratios for each matched pixel pair of the 340-and 380-nm intensity images and displayed the resulting image in pseudocolor.
